BIOCYTOGEN
6.5.2024 16:01:35 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland.
The agreement grants BioCopy access to fully human TCR-mimic antibodies targeting an intracellular antigen generated by Biocytogen’s proprietary RenTCR-mimicTM mice. BioCopy will conduct an evaluation and retain the option to license these antibodies for the development of novel cancer therapies.
“We are glad to provide BioCopy with our TCR-mimic antibodies,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Our in vivo matured TCR-mimic antibodies demonstrated favorable affinity and excellent specificity. Combined with BioCopy’s expertise in TCR-mimic antibody screening and engager development, we are optimistic that our collaboration will generate novel drugs that benefit cancer patients.”
BioCopy will use Biocytogen’s TCR-mimic antibodies and test them against promising intracellular tumor associated antigens. Here, BioCopy will use its automated end-to-end platform for the optimization of multispecific biotherapeutics to further develop these TCR-mimic antibodies into next-generation oncological drugs.
About Biocytogen’s TCR-mimic Antibody Discovery Platform
Biocytogen’s TCR-mimic platform focuses on the discovery of fully human antibodies to intracellular targets that are presented on the cell surface by MHC class I molecules. Leveraging proprietary RenTCR-mimicTM (HLA/RenMab) mice and specialized immunization protocols, Biocytogen’s platform is designed to generate TCR-mimic antibodies that are highly specific for peptide/HLA complexes and not HLA itself. Using a high-throughput antibody screening platform, Biocytogen swiftly identifies TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients to overcome tumor immune escape. Currently, antibody hits for multiple intracellular targets, including TAAs, cancer-testis antigens, mutated protein antigens, and viral protein antigens, are being evaluated in vivo and in vitro. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), the USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
About BioCopy
BioCopy is a multinational company headquartered in Switzerland with a state-of-the-art R&D facility in Germany. The company focuses on biotherapeutic drug discovery and development using their end-to-end automated, AI-powered platform. BioCopy is convinced that cancer can be cured with ingenuity and AI, supported by the extraordinary power of our body’s own immune system. With the company’s unique platform, BioCopy is working continuously to develop next-generation biotherapeutic drug candidates with unprecedented efficacy and safety, transforming today’s pharmaceutical industries.
Website: www.biocopy.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506586492/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amazfit Introduces T-Rex Dual Solar, the First AMOLED Smartwatch with Dual-Sided Solar Charging22.9.2026 13:00:00 CEST | Press release
Built for adventures beyond the grid, T-Rex Dual Solar combines a bright AMOLED display with dual-sided solar energy recovery designed to extend battery life when access to traditional power is limited. Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the T-Rex Dual Solar, a premium expedition smartwatch built for long-distance and multi-day exploration. Launching on the autumnal equinox — a day defined by the balance of sunlight and darkness — the T-Rex Dual Solar is the world’s first AMOLED smartwatch featuring a dual-sided solar charging system, combining solar collection either through the display or through an innovative glass ceramic back plate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922588618/en/ The Amazfit T-Rex Dual Solar is the world’s first AMOLED smartwatch featuring a dual-sided solar charging system, combining solar collection either through the display or through
Saildrone USVs Receive Danish Flag Registration for European Operations22.9.2026 12:45:00 CEST | Press release
Saildrone today announced that the first four Saildrone Voyager USVs (unmanned surface vehicles) have been registered in Denmark and will operate under the Danish flag, marking the first time Saildrone USVs will operate under a national flag. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922488140/en/ A Saildrone Voyager operates in the Baltic Sea in support of maritime domain awareness missions. The 10-meter USV is one of the first Saildrone platforms registered in Denmark to operate under the Danish flag. The registration establishes a clear flag-state framework for Saildrone USVs operating internationally. Working together, Saildrone and the Danish Maritime Authority developed the regulatory framework necessary to register and operate unmanned surface vehicles under the Danish flag. “We are pleased that Saildrone has chosen Denmark as the flag state for the company’s uncrewed vessels. This underscores that Denmark, as
NIQ Announces Friendly Bid to Acquire The U Group & Co Limited, Expanding Trusted Intelligence for the AI Era22.9.2026 12:45:00 CEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that its wholly-owned Australian subsidiary, Nielsen Connect Australia Pty Ltd (NIQ Australia) has launched a conditional off-market offer for all outstanding shares of The U Group & Co Limited (The U Group) as a friendly takeover bid (Offer). The U Group is an Australian-based company specializing in first-party, consumer-consented purchase data collection through its ReceiptJar app, receipt intelligence, and AI-powered data processing capabilities. In connection with the Offer, NIQ Australia has lodged its Bidder's Statement with the Australian Securities and Investments Commission and dispatched the Offer materials to shareholders of The U Group in accordance with applicable Australian regulatory requirements. The Board of The U Group has unanimously recommended that shareholders accept the Offer for the reasons set out in the Target's Statement. The Offer reflects NIQ's commitment to strengthening trust
OKX Sets a New Standard for Account Protection with OKX Shield22.9.2026 12:30:00 CEST | Press release
Up to €500,000 in account protection for customers in EuropeOKX Shield builds on industry-leading safeguards and advanced account security OKX, a leading global cryptocurrency exchange and onchain technology company with more than 150 million customers worldwide, today launched OKX Shield. OKX Shield is an integrated security product suite combining sophisticated safeguards, visible protection status and the potential for customers to be paid back up to €500,000 following a third-party account-takeover. Account takeover fraud is a challenge for all financial businesses to protect customers against, with billions lost every year in Europe. The most recent EBA and ECB data shows €4.2 billion in payment fraud across Europe in 2024, which was up from €3.5 billion in 2023. Customers are being targeted directly, with attempts to compromise their accounts across financial platforms. OKX Shield brings together account-security enhancements with a new protection program, providing up to €500,00
Infobip Predicts 7.3 Billion Black Friday and Cyber Monday Interactions as AI Reshapes the 2026 Shopping Season22.9.2026 12:26:00 CEST | Press release
New research across nine markets finds 63% of consumers have used AI when shopping, while only 19% plan to wait until Black Friday week to begin their holiday shopping Global AI-first cloud communications platform Infobip predicts more than 7.3 billion customer interactions across Black Friday and Cyber Monday 2026, as AI and conversational channels transform how consumers discover products, receive offers and access support. New Infobip research also reveals that 63.2% of consumers have used an AI assistant or chatbot while shopping during the past 12 months. Black Friday is no longer a single shopping event. Infobip’s research shows that the shopping season now begins weeks earlier and continues through the entire customer journey. Nearly six in ten respondents will have started holiday shopping by early November, while only 19% wait until Black Friday week itself. This extended shopping window is creating new pressure for retailers to engage customers earlier, with better timing, mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom